Loading company…
PEP-Therapy develops peptide-based cancer therapies, including for pancreatic cancer and ovarian adenocarcinoma, from Paris.
Founded in 2014 and headquartered in Paris, France, PEP-Therapy develops peptide-based cancer therapies. Its lead product, PEP-010, has FDA Orphan Drug Designation for pancreatic cancer. On July 22, 2021, the company raised EUR 1.573 mn in a Series A led by Eurazeo PME, with Business Angels Des Grandes Ecoles and i&i Prague participating. CEO Antoine PRESTAT has led it since its inception.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in